COMPANY NEWS
September 29, 2023
Novel DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer
July 16, 2023
India patent registration opens door to commercial agreements in an enormous market with high economic potential for CureLab Oncology
March 3, 2023
Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals
November 5, 2022
CureLab Oncology and CureLab Veterinary are looking for interns to work with our FDA/USDA team on regulatory activities
September 10, 2022
While the disease has progressed in all patients receiving standard of care, it did not progress in 40% of the patients receiving standard chemotherapy together with the experimental drug, Elenagen — and for half of the patients in the group, Elenagen has increased the time to disease progression by more than 2.5 times